{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"TroFuse-019","nct_id":"NCT06312137","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-019-nct06312137. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TroFuse-019","arms":[{"description":"Participants will receive pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by sacituzumab tirumotecan 4 mg/kg IV infusion every 2 weeks (Q2W) for up to 12 doses (\\~24 weeks) with pembrolizumab monotherapy 200 mg IV infusion every 6 weeks (Q6W) for up to 7 cycles (\\~42 weeks).","label":"Pembrolizumab + Sacituzumab tirumotecan","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab 200 mg intravenous (IV) infusion Q3W for up to 12 weeks + double-platinum chemotherapy per neoplasm histology classification at the investigator's discretion as neoadjuvant therapy prior to surgery; followed by pembrolizumab monotherapy 200 mg IV infusion Q6W for up to 7 cycles (\\~42 weeks).","label":"Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2034-10-23","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":780,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sacituzumab tirumotecan","otherNames":["MK-2870","sac-TMT","SKB264"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475"],"type":"BIOLOGICAL"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Rescue medication","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2034-02-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to ~ 93 months"}],"references":[],"start_date":{"date":"2024-04-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","url":"https://clinicaltrials.gov/study/NCT06312137"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-019-nct06312137"}